- $1.84bn
- $1.82bn
- $105.97m
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
Brief: Zymeworks Appoints Suzanne Monahan As Senior Vice President, Commercial And General Manager, Theravance Biopharma
Brief: Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
Zymeworks Inc. reports results for the quarter ended June 30 - Earnings Summary
Zymeworks Inc. expected to post a loss of 46 cents a share - Earnings Preview
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Zymeworks falls after $929 million Theravance buyout deal
Deals of the day-Mergers and acquisitions
Zymeworks expands beyond cancer with $929 million Theravance acquisition (updated)
Theravance slips after Zymeworks' $929 mln buyout deal